Journal
ISCIENCE
Volume 24, Issue 9, Pages -Publisher
CELL PRESS
DOI: 10.1016/j.isci.2021.102937
Keywords
-
Categories
Funding
- NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) [75N93019C00051]
- NIAID Center of Excellence for Influenza Research and Surveillance (CEIRS) [HHSN272201400008C]
- JPB Foundation
- Open Philanthropy Project [2020-215611 (5384)]
- Serological SciencesNetwork (SeroNet)
- National Cancer Institute, National Institutes of Health [75N91019D00024, 75N91020F00003]
Ask authors/readers for more resources
This study analyzed the antibody responses of healthcare workers using different serological tests, finding a good correlation between RBD and spike-based assays. Antibody levels in HCWs declined over time, while the seroprevalence of NP-reactive antibodies significantly decreased.
Current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serological tests are based on the full-length spike (S), the receptor-binding domain (RBD), or the nucleoprotein (NP) as substrates. Here, we used samples from healthcare workers (HCWs) to perform a longitudinal analysis of the antibody responses using a research-grade RBD and spike-based enzyme-linked immunosorbent assay (ELISA), a commercial RBD and spike-based ELISA, and a commercial NP-based chemiluminescent microparticle immunoassay. Seroprevalence ranged around 28% early during the pandemic and a good correlation was observed between RBD and spike- based ELISAs. Modest correlations were observed between NP and both RBD and spike-based assays. The antibody levels in HCWs declined over time; however, the overall seroprevalence measured by RBD and spike-based assays remained unchanged, while the seroprevalence of NP-reactive antibodies significantly declined. Moreover, RBD and spike-based assays effectively detected seroconversion in vaccinees. Overall, our results consolidate the strength of different serological assays to assess the magnitude and duration of antibodies to SARS-CoV-2.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available